Loading...
Market
What will be VTAMA Cream's market share in the dermatologic therapy market by December 31, 2025?
2
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Market research reports from firms like Nielsen or IQVIA
Story
Organon to Acquire Roivant's Dermavant for Up to $1.2 Billion, Including VTAMA Cream
Sep 18, 2024, 01:15 PM
Organon has announced its acquisition of Dermavant, a subsidiary of Roivant Sciences, in a deal valued at up to $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream 1%. Organon will pay $175 million upfront, with additional payments contingent on regulatory approval and sales milestones. Specifically, $75 million will be paid upon approval of VTAMA for atopic dermatitis, and up to $950 million will be paid based on sales milestones. Roivant's stock rose 2.2% pre-market following the announcement. The deal has received mixed reactions from analysts, with some expressing concerns about its impact on Organon, while others view it as positive for Roivant.
View original story
Similar markets
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
None • 25%
Up to $200 million • 25%
$200 million to $600 million • 25%
Above $600 million • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%